On the other hand, several other studies suggested that the risk of incident AF in T2D patients could be reduced with intensive blood pressure lowering therapy [12], biguanides (metformin) and thiazolidinediones [13], or dipeptidyl peptidase-4 (DPP-4) inhibitor therapy [14]. The gene discussed is DPP4; the disease is atrial fibrillation.